Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.12.3463 on September 4 2007

Journal of Clinical Oncology, Vol 25, No 28 (October 1), 2007: pp. 4459-4465
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palumbo, A.
Right arrow Articles by Petrucci, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palumbo, A.
Right arrow Articles by Petrucci, M. T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

Antonio Palumbo, Patrizia Falco, Paolo Corradini, Antonietta Falcone, Francesco Di Raimondo, Nicola Giuliani, Claudia Crippa, Giovannino Ciccone, Paola Omedè, Maria Teresa Ambrosini, Francesca Gay, Sara Bringhen, Pellegrino Musto, Robin Foà, Robert Knight, Jerome B. Zeldis, Mario Boccadoro, Maria Teresa Petrucci

From the Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Torino; Divisione di Ematologia, Istituto Nazionale Tumori, Milano; UO Ematologia e Trapianto di Cellule Staminali, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; Cattedra di Ematologia, Ospedale Ferrarotto, Catania; Cattedra e UO Ematologia e Trapianti midollo, Università degli Studi di Parma, Parma; Sezione Ematologia, Università di Brescia, Spedali Civili, Brescia; Servizio di Epidemiologia dei Tumori dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Torino, e CPO Piemonte; UO di Ematologia e Trapianto di Cellule Staminali, CROB - Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture; Dipartimento di Biotecnologie e Ematologia, Università La Sapienza, Roma, Italy; and the Celgene Corporation, Summit, NJ

Address reprint requests to Antonio Palumbo, MD, Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Via Genova 3, 10126 Torino, Italy; e-mail: appalumbo{at}yahoo.com

Purpose Lenalidomide has shown significant antimyeloma activity in clinical studies. Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients. We assessed dosing, efficacy, and safety of melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed elderly myeloma patients.

Patients and Methods Oral melphalan was administered in doses ranging from 0.18 to 0.25 mg/kg on days 1 to 4, prednisone at a 2-mg/kg dose on days 1 to 4, and lenalidomide at doses ranging from 5 to 10 mg on days 1 to 21, every 28 days for nine cycles, followed by maintenance therapy with lenalidomide alone. Aspirin was given as a prophylaxis for thrombosis.

Results Fifty-four patients were enrolled and evaluated after completing the assigned treatment schedule. The maximum tolerated dose was defined as 0.18 mg/kg melphalan and 10 mg lenalidomide. With these doses, 81% of patients achieved at least a partial response, 47.6% achieved a very good partial response, and 23.8% achieved a complete immunofixation-negative response. In all patients, 1-year event-free and overall survival rates were 92% and 100%, respectively. At the maximum tolerated dose, grade 3 adverse events included neutropenia (38.1%), thrombocytopenia (14.2%), febrile neutropenia (9.5%), vasculitis (9.5%), and thromboembolism (4.8%); grade 4 adverse events were neutropenia (14.2%) and thrombocytopenia (9.5%).

Conclusion Oral MPR therapy is a promising first-line treatment for elderly myeloma patients. Hematologic adverse events were frequent but manageable. A low incidence of nonhematologic adverse events was noted. Aspirin appears to provide adequate antithrombosis prophylaxis.

published online ahead of print at www.jco.org on September 4, 2007.

Sponsored by the Università degli Studi di Torino, Italy, and supported in part by research funding from Celgene Corporation (Summit, NJ; to M.B.) and by Fondazione Neoplasie Sangue Onlus, Associazione Italiana Leucemie, Compagnia di S. Paolo, Associazione per lo Studio e la Cura delle Malattie del Sangue, Fondazione Cassa di Risparmio di Torino, Ministero Università Ricerca Scientifica e Tecnologia (MIUR), and Consiglio Nazionale delle Ricerche (CNR).

Presented in part in abstract format at European Hematology Association, Amsterdam, the Netherlands, June 15-18, 2006; American Society of Clinical Oncology, Atlanta, GA, June 4-6, 2006; American Society of Hematology, Atlanta, GA, December 10-13, 2005; and the American Society of Hematology, Orlando, FL, December 9-12, 2006.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
A. Palumbo, F. Gay, P. Falco, C. Crippa, V. Montefusco, F. Patriarca, F. Rossini, S. Caltagirone, G. Benevolo, N. Pescosta, et al.
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
J. Clin. Oncol., February 10, 2010; 28(5): 800 - 807.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. F. de Larrea, M. T. Cibeira, M. Elena, J. I. Arostegui, L. Rosinol, M. Rovira, X. Filella, J. Yague, and J. Blade
Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition
Blood, December 3, 2009; 114(24): 4954 - 4956.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. G. Richardson, E. Weller, S. Jagannath, D. E. Avigan, M. Alsina, R. L. Schlossman, A. Mazumder, N. C. Munshi, I. M. Ghobrial, D. Doss, et al.
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
J. Clin. Oncol., December 1, 2009; 27(34): 5713 - 5719.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al.
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Mayo Clin. Proc., December 1, 2009; 84(12): 1095 - 1110.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Falanga and M. Marchetti
Venous Thromboembolism in the Hematologic Malignancies
J. Clin. Oncol., October 10, 2009; 27(29): 4848 - 4857.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood, October 8, 2009; 114(15): 3139 - 3146.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Hulin, T. Facon, P. Rodon, B. Pegourie, L. Benboubker, C. Doyen, M. Dib, G. Guillerm, B. Salles, J.-P. Eschard, et al.
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
J. Clin. Oncol., August 1, 2009; 27(22): 3664 - 3670.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Reece, K. W. Song, T. Fu, B. Roland, H. Chang, D. E. Horsman, A. Mansoor, C. Chen, E. Masih-Khan, Y. Trieu, et al.
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Blood, July 16, 2009; 114(3): 522 - 525.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J.-L. Harousseau and P. Moreau
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654.
[Full Text] [PDF]


Home page
BloodHome page
H. Ludwig, R. Hajek, E. Tothova, J. Drach, Z. Adam, B. Labar, M. Egyed, I. Spicka, H. Gisslinger, R. Greil, et al.
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Blood, April 9, 2009; 113(15): 3435 - 3442.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al.
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Clin. Cancer Res., January 15, 2009; 15(2): 520 - 531.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. A. Dawson, S. S. Opat, Y. Taouk, M. Donovan, M. Zammit, K. Monaghan, N. Horvath, A. W. Roberts, H. M. Prince, M. Hertzberg, et al.
Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma
Clin. Cancer Res., January 15, 2009; 15(2): 714 - 722.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
A. Palumbo and F. Gay
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing
Hematology, January 1, 2009; 2009(1): 566 - 577.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Palumbo, S. Bringhen, A. M. Liberati, T. Caravita, A. Falcone, V. Callea, M. Montanaro, R. Ria, A. Capaldi, R. Zambello, et al.
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Blood, October 15, 2008; 112(8): 3107 - 3114.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. F. San Miguel, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, et al.
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
N. Engl. J. Med., August 28, 2008; 359(9): 906 - 917.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. G.M. Durie
Treatment of Myeloma -- Are We Making Progress?
N. Engl. J. Med., August 28, 2008; 359(9): 964 - 966.
[Full Text] [PDF]


Home page
JCOHome page
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
E. N. Brown and J. D. Herrington
Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment
Journal of Pharmacy Practice, April 1, 2008; 21(2): 126 - 137.
[Abstract] [PDF]


Home page
JCOHome page
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. A. Kyle and S. V. Rajkumar
Multiple myeloma
Blood, March 15, 2008; 111(6): 2962 - 2972.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J.-L. Harousseau
Induction Therapy in Multiple Myeloma
Hematology, January 1, 2008; 2008(1): 306 - 312.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online